BAC free glaucoma therapy welcomed in Japan

Article

The Ministry of Health, Labour and Welfare in Japan has approved Alcon's treatment for glaucoma and ocular hypertension, TRAVATANZ 0.004%.

The Ministry of Health, Labour and Welfare in Japan has approved Alcon's treatment for glaucoma and ocular hypertension, TRAVATANZ 0.004%.

TRAVATANZ is the first prostaglandin analogue that does not contain benzalkonium chloride (BAC), a preservative that is commonly used in topical ocular medications. Recent research has suggested that BAC could negatively affect the ocular surface. To this end, Alcon developed TRAVATANZ as a BAC free version of it glaucoma therapy, TRAVATAN.

TRAVATANZ was approved as TRAVATAN Z in the US in 2006.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.